The Board of Directors, comprised of leading asthma experts, is GINA’s main governing body. It encourages dissemination and adoption of the reports on asthma management through utilization of existing health care structures in individual countries and promotes international collaboration on asthma research.
The GINA Board of Directors meets several times a year to discuss and plan programs and activities to carry out the goals of the GINA program.
Guy Brusselle, MD, PhD, FERS, Chair
Ghent University
Ghent, Belgium
Ghent University Hospital
Ghent, Belgium
Keith Allan, CBiol, MRSB
Patient Partner
University Hospitals of Leicester
Leicester, United Kingsom
Muhwa Jeremiah Chakaya, MD
Kenyatta University
Nairobi, Kenya
Pulmonologist
Nairobi, Kenya
Alvaro A. Cruz, MD
Federal University of Bahia and Fundacao ProAR
Salvador, Brazil
Hospital Aliança – Rede D’Or
Salvador, Brazil
Hiromasa Inoue, MD
Kagoshima University
Kagoshima, Japan
Imamura General Hospital, Jiaikai Public Interest Incorporated Foundation
Kagoshima, Japan
Jerry A. Krishnan, MD, PhD
Division of Pulmonary, Critical Care, Sleep, and Allergy
University of Illinois Hospital and Health Sciences System
Chicago, Illinois, USA
Mark L. Levy, MD
General Practitioner
London, United Kingdom
Helen K. Reddel, MBBS, PhD
Macquarie University and University of Sydney
Sydney, NSW, Australia
Sydney Local Health District
Sydney, NSW, Australia
Arzu Yorgancioglu, MD
Celal Bayar University Medical Faculty
Department of Pulmonary Diseases
Manisa, Turkey
GINA Committee members disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations in December of each year using the following definitions:
Non-Personal Interests refers to fees or grants paid to a GINA Committee member (or the Department/Institution on behalf of a GINA member) and used for research, education, equipment, salaries, etc.
Personal Benefits (Consultancy-Lecture Fees) refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.
Shares refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/children). The company is to be listed, not the number of shares.
View Board and Committee Annual Disclosures